期刊
PRENATAL DIAGNOSIS
卷 31, 期 1, 页码 7-15出版社
WILEY-BLACKWELL
DOI: 10.1002/pd.2637
关键词
first-trimester screening; trisomy 21; aneuploidies; nuchal translucency; serum PAPP-A; serum free beta-hCG
资金
- Fetal Medicine Foundation [1037116]
Effective screening for major aneuploidies can be provided in the first trimester of pregnancy. Screening by a combination of fetal nuchal translucency and maternal serum free-beta-human chorionic gonadotrophin and pregnancy-associated plasma protein-A can identify about 90% of fetuses with trisomy 21 and other major aneuploidies for a false-positive rate of 5%. Improvement in the performance of first-trimester screening can be achieved by firstly, inclusion in the ultrasound examination assessment of the nasal bone and flow in the ductus venosus, hepatic artery and across the tricuspid valve, and secondly, carrying out the biochemical test at 9 to 10 weeks and the ultrasound scan at 12 weeks. Copyright (C) 2011 John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据